Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). Enzymatica AB's share price for the quarter that ended in Mar. 2026 was €0.26. Enzymatica AB's Shares Outstanding (EOP) for the quarter that ended in Mar. 2026 was 242.74 Mil. Therefore, Enzymatica AB's market cap for the quarter that ended in Mar. 2026 was €63.11 Mil.
Enzymatica AB's quarterly market cap
declined
from Sep. 2025 (€48.06 Mil) to Dec. 2025 (€40.78 Mil) but then
increased
from Dec. 2025 (€40.78 Mil) to Mar. 2026 (€63.11 Mil).
Enzymatica AB's annual market cap
declined
from Dec. 2023 (€55.19 Mil) to Dec. 2024 (€30.83 Mil) but then
increased
from Dec. 2024 (€30.83 Mil) to Dec. 2025 (€40.78 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Enzymatica AB's Enterprise Value for Today is €50.19 Mil.
Enzymatica AB (STU:EN9) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
Enzymatica AB Market Cap Related Terms
Enzymatica AB Market Cap Historical Data
* Premium members only.
The historical data trend for Enzymatica AB's Market Cap can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Enzymatica AB's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Enzymatica AB Market Cap vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Enzymatica AB's Market Cap distribution charts can be found below:
* The bar in red indicates where Enzymatica AB's Market Cap falls into.
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
Enzymatica AB's Market Cap for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enzymatica AB (STU:EN9) has a Market Cap of €52.48 Mil as of Jul. 02, 2026. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Enzymatica AB and its competitors. According to the industry distribution chart, Enzymatica AB ranks #683 out of 1024 companies in the Drug Manufacturers industry, placing it in the top 66.7%.
Is Enzymatica AB's Market Cap too high?
Enzymatica AB's current Market Cap is €52.48 Mil. Based on the distribution chart, Enzymatica AB ranks #683 out of 1024 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Enzymatica AB has a GF Score™ of 58/100, reflecting its overall financial health beyond just this single metric.
How does Enzymatica AB's Market Cap compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Enzymatica AB ranks #683 out of 1024 companies for Market Cap. This places Enzymatica AB in the lower half of its industry. The industry median Market Cap is 212.74. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Market Cap for a Drug Manufacturers company?
The median Market Cap among Drug Manufacturers companies is 212.74, based on 1,024 companies in the industry. Companies in the top quartile (top 25%) have a Market Cap significantly above this median, while those in the bottom quartile fall well below. However, Market Cap should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Market Cap mean?
A high Market Cap can signal that a stock is expensive relative to its fundamentals. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Enzymatica AB and its competitors. For the Drug Manufacturers industry, the median Market Cap is 212.74 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Enzymatica AB's current Market Cap is €52.48 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Enzymatica AB stock overvalued right now?
Enzymatica AB (STU:EN9) has a current Market Cap of €52.48 Mil. The stock's GF Value™ is €0.16, compared to a current price of €0.19 — trading 16.6% above its estimated fair value. The current Market Cap is €52.48 Mil. Enzymatica AB's overall GF Score™ is 58/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Market Cap calculated?
Market Cap is calculated from a company's financial statements. For Enzymatica AB (STU:EN9), the current Market Cap is €52.48 Mil as of Jul. 02, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Enzymatica AB (STU:EN9) Overvalued in 2026?
Based on GuruFocus' analysis, Enzymatica AB stock appears to be overvalued.
The current stock price of €0.19 is trading 16.6% above its estimated GF Value™ of €0.16.
Key valuation signals for STU:EN9:
Market Cap: €52.48 Mil
GF Value™: €0.16 vs. price of €0.19 (16.6% above fair value)
No single metric tells the full story. See the STU:EN9 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Enzymatica AB is a life science company that develops and sells medical devices against infectious diseases, based on a barrier technology, which includes marine enzymes. Its product ColdZyme Mouth Spray prevents cold and reduces disease period.
58GF Score
Get the complete analysis for STU:EN9
Market Cap is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:EN9 has been successfully added to your 
